MHLW Sets Donations Limit Of ¥5 Million To Drug Review Board Members
This article was originally published in PharmAsia News
Japan's Ministry of Health, Labor and Welfare has set a maximum ¥5 million per year as the donations limit to its outside drug review board members. The ruling also pertains to competitors of a pharmaceutical company that is applying for a new drug approval. Since last April, when a research team inside MHLW was found to have received large donations from Tamiflu's Japanese importer, the Ministry has strengthened rules on receiving donations from drug companies. (Click here for more - Japanese language
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.